Biosimilar Newsletter Archive

1. 03.19.26 -- Struggling with mAb aggregation and other impurities? 3/19/2026

   03/19/26 Biosimilar Development Newsletter

2. 03.19.26 -- A Novel In Vitro Glycosylation Approach For Difficult PTMs 3/19/2026
   03/19/26 Biosimilar Development Newsletter
3. 03.05.26 -- Phase-Appropriate Control Lessons For mAb/ADC Manufacturers 3/5/2026
   03/05/26 Biosimilar Development Newsletter
4. 02.26.26 -- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment 2/26/2026
   02/26/26
5. 02.19.26 -- Why Use Total Organic Carbon Analysis For Cleaning Validation? 2/19/2026
   02/19/26 Biosimilar Development Newsletter
6. 02.12.26 -- Building Enterprise Resilience From QRM Signals 2/12/2026
   02/12/26 Biosimilar Development Newsletter
7. 01.29.26 -- The Latest In Upstream HCP Mitigation 1/29/2026
   01/29/26 Biosimilar Development Newsletter
8. 01.15.26 -- SUS Insufficient For 40% Of Biopharma 1/15/2026
   01/15/26 Biosimilar Development Newsletter
9. 01.08.26 -- What 2025 FDA Warning Letters Tell Us About GMP Compliance 1/8/2026
   01/08/26 Biosimilar Development Newsletter
10. 12.18.25 -- Why Your MVP And Its Evolution Matters To Manufacturing 12/18/2025
    12/18/25 Biosimilar Development Newsletter